Business Context and Reporting Period
Company: SRx Health Solutions, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2026
Reporting Period: As of March 2, 2026 (Date of earliest event reported)
This filing reports the entry into a Material Definitive Agreement regarding a new securities offering and the waiver of participation rights by existing investors.
Key Financial Metrics
This Form 8-K does not contain audited financial statements, revenue, profit, cash flow, or margin data. It focuses on capital structure transactions. Relevant historical financing figures disclosed include:
- July 2025 Note Financing: Issued senior secured convertible notes with an aggregate original principal amount of $7,650,000.
- October 2025 Series A Financing: Issued 19,035 shares of Series A Preferred Stock and 54,527,811 Series A Warrants for aggregate proceeds of approximately $15.23 million.
- Proposed Series B Offering: The filing announces a new offering of Series B Preferred Stock and related warrants, but does not disclose the specific aggregate purchase price or number of shares for this new transaction.
Material Changes and Agreements
The primary material change is the execution of a "New Securities Purchase Agreement" with new accredited investors ("New Buyers") for the issuance of Series B Preferred Stock and warrants. Key terms include:
- Waiver of Participation Rights: Certain existing investors (from the July 2025 Note Financing and October 2025 Series A Financing) have entered into limited waiver and consent agreements. They have agreed to waive their right to participate in the New Offering and any subsequent placements.
- Creation of Parity Stock: Existing investors acting as "Required Holders" have consented to the creation of Parity Stock. This allows the new Series B Preferred Stock to rank pari passu (equal) with the Series A Preferred Stock regarding dividends, distributions, and liquidation preferences.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Company's desire to raise additional capital through the New Offering. The text does not provide specific guidance on future revenue, earnings, or operational outlook.
Risks and Contingencies:
- Dilution: The issuance of new Series B Preferred Stock and warrants will result in dilution to existing shareholders.
- Capital Structure Complexity: The creation of Parity Stock alters the seniority and preference structure of the Company's equity, potentially impacting the rights of Series A holders in liquidation scenarios.
- Future Closings: The New Offering is structured to be completed in one or more closings, implying uncertainty regarding the final timing and total capital raised.
Investor Verification Checklist
- Verify the specific terms of the Series B Preferred Stock (conversion rate, dividend rate, maturity) in the Certificate of Designations referenced in the filing.
- Confirm the total aggregate purchase price and number of shares/warrants to be issued in the New Offering, as these figures are not explicitly stated in this summary text.
- Review the full text of the "Form of Waiver" (Exhibit 10.1) to understand the specific conditions under which existing investors waived their participation rights.
- Assess the impact of the new Parity Stock on the liquidation preference hierarchy relative to the Series A Preferred Stock.